What if a bladder treatment could turn the bladder’s own cells into factories for an anticancer signal? This review explains how nadofaragene firadenovec delivers interferon directly where it is needed, then uses both tumor-killing and immune mechanisms.

Effective bladder-preserving therapeutic options are needed for patients with bacillus Calmette-Guérin unresponsive non–muscle-invasive bladder cancer. Nadofaragene firadenovec-vncg, also called Adstiladrin, was approved by the US Food and Drug Administration as the first gene therapy in urology and the first intravesical gene therapy for adults with high-risk bacillus Calmette-Guérin–unresponsive non–muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

The proposed mechanism underlying nadofaragene firadenovec efficacy is likely due to the pleiotropic nature of interferon-a and its direct and indirect antitumor activities. Direct activities include cell death and an antiangiogenic effect, while indirect activities begin through immunomodulation of the innate and adaptive immune responses.

Sustained expression of interferon-a contributes to a durable response. With high-risk non–muscle-invasive bladder cancer, patients have a 60 to 70 percent likelihood of recurrence and a 10 to 45 percent risk of progression to muscle-invasive or metastatic bladder cancer within five years.

BCG-unresponsive non–muscle-invasive bladder cancer is associated with poor prognosis and historically few treatment options. Radical cystectomy has remained the standard of care for BCG-unresponsive disease and is preferred for high-risk disease in multiple guidelines, but it is not appropriate for all patients.

For patients who are ineligible for, or choose not to undergo, radical cystectomy, treatment options include intravesical chemotherapy, pembrolizumab, and nadofaragene firadenovec. Nadofaragene firadenovec is instilled intravesically every three months and has a well-tolerated safety profile, with micturition urgency being the most common grade three or four study-drug-related adverse event.

The bladder urothelium is a complex, multilayer surface that acts as a barrier to pathogens and urinary waste products. Efficient viral transduction of the urothelium therefore requires a robust means to permeate the protective glycosaminoglycan layer of the bladder mucosa.

Syn3 is a polyamide surfactant and synthetic excipient that promotes adenoviral transduction across the glycosaminoglycan layer of the inner bladder wall. When adenovirus was administered in a formulation containing Syn3, adenoviral-mediated gene transfer and expression markedly increased in normal urothelial cells and in human superficial transitional cell carcinoma growing in athymic nude mice.

Nadofaragene firadenovec is a nonreplicating adenoviral vector-based gene therapy that delivers human IFNa2b complementary DNA to urothelial cells. Syn3 enhances viral transduction of the urothelium, helping the vector deliver its genetic payload across the bladder surface.

IFNa2b complementary DNA is transcribed into IFNa2b protein in bladder epithelial cells, where it exhibits direct and indirect immunomodulatory effects inhibiting tumor growth. Figure one maps nadofaragene firadenovec from delivery to antitumor activity.

In panel A, Syn three helps the adenoviral vector cross the bladder’s protective surface, enter urothelial cells through the CAR receptor, and drive sustained production of interferon alpha two b. Panel B then summarizes direct effects such as tumor-cell death and antiangiogenesis, alongside immune effects involving MHC class one, dendritic cells, cytotoxic T cells, and natural killer cells.

Elevated bladder tissue IFNa levels were observed for at least seven days following nadofaragene firadenovec therapy compared with recombinant human IFNa levels, which declined rapidly after treatment. This discovery emphasized the benefit of gene therapy in overcoming the issue of durability with intravesically administered recombinant human IFNa.

In a multicenter phase two trial, forty patients with high-grade BCG-refractory or relapsed non–muscle-invasive bladder cancer were randomly assigned to low- or high-dose intravesical nadofaragene firadenovec. Freedom from high-grade disease recurrence at twelve months was similar between dose groups: seven patients, or thirty-three percent, in the low-dose group and seven patients, or thirty-seven percent, in the high-dose group achieved twelve-month recurrence-free survival.

In subgroup analyses, twelve-month recurrence-free survival was fifty percent for patients with papillary disease and thirty percent for patients with carcinoma in situ. The most common adverse events were lower urinary tract symptoms; no grade four or five adverse events occurred, and no patient discontinued therapy because of an adverse event.

In the carcinoma in situ group, with or without high-grade Ta or T1 disease, fifty-three point four percent of patients had a complete response at three months, and forty-five point five percent maintained that response through twelve months. In the high-grade Ta or T1 cohort, seventy-two point nine percent of patients had a complete response at three months, with forty-three point eight percent remaining recurrence-free through twelve months.

The most frequently reported drug-related adverse events were discharge around the catheter during instillation, fatigue, bladder spasms, and micturition urgency. Most adverse events were transient and classified as either grade one or two, with a low discontinuation rate of one point nine percent and no treatment-related deaths during twelve months of follow-up.

Nadofaragene firadenovec is the first FDA-approved gene therapy for high-risk BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. Its mechanism of action is hypothesized to result through direct and indirect IFNa2b activity.

Direct biological responses include apoptosis and angiogenesis inhibition, affecting tumor-cell initiation and progression. Indirect activity occurs through immunoregulation: stimulating natural-killer and T cells, and increasing antigen presentation by macrophages and dendritic cells, which augments a more robust immune response.

The central idea is that nadofaragene firadenovec combines adenoviral gene delivery with sustained interferon activity, producing direct antitumor effects and broader immune modulation. That combination helps explain its potential as a bladder-preserving option.